Protagonist Therapeutics, Inc
https://www.polycythemiavera-clinicaltrial.com/
Welcome to Protagonist, a clinical-stage biopharmaceutical company. We strive to improve patients’ lives through the power of peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate.
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities, rusfertide and PN-235, in different stages of clinical development, both derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate. VERIFY, the global Phase 3 registrational study of rusfertide in polycythemia vera, is currently underway.